OUR PRESS RELEASES AND NEWS UPDATES

Press releases
News updates

These press releases and news updates are intended for media and investors only

ViiV Healthcare announces positive data demonstrating long-acting injectable Cabenuva (cabotegravir, rilpivirine) is as effective as daily oral Biktarvy (BIC/FTC/TAF) for the treatment of HIV-1

23 Feb 2023
ViiV Healthcare receives EU Marketing Authorisation for Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV in Europe

22 Feb 2023
ViiV Healthcare to present first head-to-head data for long-acting HIV treatment Cabenuva against daily oral Biktarvy at CROI 2023

14 Feb 2023
ViiV Healthcare announces CHMP positive opinion for Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV in Europe

16 Dec 2022
ViiV Healthcare unveils a new global study revealing three quarters of people believe there are still negative perceptions when it comes to people living with hiv

01 Dec 2022
European Medicines Agency validates ViiV Healthcare’s marketing authorisation application for cabotegravir long-acting injectable for HIV Prevention

28 Oct 2022
ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV

25 Oct 2022
ViiV Healthcare presents positive data showing Vocabria (cabotegravir) and Rekambys (rilpivirine) can be successfully implemented across a range of European healthcare settings

24 Oct 2022
ViiV Healthcare to showcase innovative HIV treatment and prevention portfolio at IDWeekᵀᴹ and HIV Glasgow

12 Oct 2022
ViiV Healthcare presents positive five-year data at AIDS 2022, demonstrating the durability of fostemsavir in people living with HIV who are heavily treatment-experienced

29 Jul 2022
ViiV Healthcare announces new data at AIDS 2022 from unblinded phase of HPTN 084 study in women in sub Saharan Africa showing continued superior efficacy of injectable cabotegravir long-acting for PrEP over daily, oral TDF/FTC tablets

28 Jul 2022
ViiV Healthcare and the Medicines Patent Pool sign new voluntary licensing agreement to expand access to innovative long-acting HIV prevention medicine

28 Jul 2022
AVAC, BMGF, CIFF, MedAccess, Unitaid and ViiV Healthcare announce collaboration to catalyse more affordable access to long-acting cabotegravir for HIV prevention

28 Jul 2022
ViiV Healthcare to present new data from innovative HIV treatment and prevention portfolio at AIDS 2022

25 Jul 2022
ViiV Healthcare announces marketing approval by Japan’s Ministry of Health, Labour and Welfare for Vocabria (cabotegravir) used in combination with Rekambys (rilpivirine), the first and only complete long-acting treatment for HIV

31 May 2022
ViiV Healthcare commits to grant voluntary licence for patents relating to cabotegravir long-acting for prep to medicines patent pool

27 May 2022
ViiV Healthcare ranked #1 for the ninth successive year in PatientView’s ‘Corporate Reputation of Pharma – from the Patient Perspective 2021 - 2022’ survey results

26 Apr 2022
ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV

30 Mar 2022
ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period

24 Mar 2022

ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period
ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022

07 Feb 2022
GSK announces settlement between ViiV Healthcare and Gilead Sciences, Inc. resolving litigation relating to Biktarvy and ViiV’s dolutegravir patents and entry into a patent licence agreement

01 Feb 2022
ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment

01 Feb 2022
ViiV Healthcare announces FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention

21 Dec 2021
Forty years on from the start of the HIV epidemic, new data reveals people living with HIV face outdated attitudes and ongoing discrimination

01 Dec 2021
ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine), the first long-acting HIV-treatment regimen, can be implemented successfully in a variety of European healthcare settings

28 Oct 2021
ViiV Healthcare announces European Commission Decision for Vocabria (cabotegravir) and Rekambys (rilpivirine) injections to be initiated with or without an oral lead-in period for the long-acting treatment of HIV

28 Oct 2021
Less talk, more action: New report sponsored by ViiV Healthcare provides roadmap to achieve health equity by 2040

20 Oct 2021
ViiV Healthcare submits FDA application for first dispersible single tablet regimen containing dolutegravir (DTG) for children living with HIV

04 Oct 2021
ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs

29 Sep 2021
ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals

28 Sep 2021
FDA grants Priority Review to ViiV Healthcare’s New Drug Application for cabotegravir long-acting for prevention of HIV

28 Sep 2021
ViiV Healthcare to present key data that provides further support for the use of 2-drug regimens, including long-term efficacy, alongside new insights into living with HIV at IDWeek 2021

22 Sep 2021
ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19

17 Jul 2021
ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs

17 Jul 2021
ViiV Healthcare to present new data from diverse portfolio and pipeline of 2-drug and long-acting regimens for HIV treatment and prevention at IAS 2021

17 Jul 2021
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra-long-acting” medicines for HIV

22 Jun 2021
ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV

04 May 2021
ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV

09 Mar 2021
ViiV Healthcare presents data for long-acting cabotegravir and rilpivirine for the treatment of HIV showing continued virologic suppression to 96 weeks

06 Mar 2021
ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside pipeline advances at CROI 2021

02 Mar 2021
ViiV Healthcare receives Marketing Authorisation for Rukobia (fostemsavir), a first-in-class attachment inhibitor in combination with other antiretrovirals for the treatment of adults with multidrug-resistant HIV

08 Feb 2021
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment

21 Jan 2021
ViiV Healthcare and Chelsea and Westminster Hospital continue their innovation partnership to launch new digital services to transform HIV patient care

18 Jan 2021
ViiV Healthcare receives EU Marketing Authorisation for the first-ever dispersible-tablet formulation of dolutegravir, Tivicay, a treatment for children living with HIV in Europe

13 Jan 2021
ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe

21 Dec 2020
ViiV Healthcare announces positive CHMP opinion for Rukobia (fostemsavir), a first-in-class attachment inhibitor for the treatment of adults with multidrug-resistant HIV with few treatment options available

11 Dec 2020
ViiV Healthcare and Shutterstock Studios unite to tackle outdated perceptions of HIV with ‘HIV in View’ - a first-of-its-kind online HIV photography gallery

01 Dec 2020
ViiV Healthcare and the Medicines Patent Pool expand access to dolutegravir-based regimens for people living with HIV in Azerbaijan, Belarus, Kazakhstan and Malaysia with innovative new licensing agreement

30 Nov 2020
ViiV Healthcare announces results of the PROgress study demonstrating that the inclusion of patient reported outcomes into clinical practice can improve HIV care

18 Nov 2020
ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention

17 Nov 2020
ViiV Healthcare announces CHMP positive opinion for the first-ever dispersible-tablet formulation of dolutegravir, Tivicay, a treatment for children living with HIV in Europe

13 Nov 2020
ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women

09 Nov 2020
ViiV Healthcare presents positive new findings from two studies of its investigational, long-acting regimen of cabotegravir and rilpivirine, including five-year data showing long-term durability, efficacy, safety, and tolerability

22 Oct 2020
ViiV Healthcare presents continued positive findings from first-ever implementation science study on integrating an investigational once-monthly injectable HIV treatment into US healthcare practices

22 Oct 2020
ViiV Healthcare announces analysis showing no antiretroviral therapy interruptions due to COVID-19 across its clinical development programme for investigational, long-acting cabotegravir and rilpivirine

21 Oct 2020
ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV

16 Oct 2020
ViiV Healthcare presents long-term switch data for Dovato demonstrating non-inferior efficacy in adults with HIV-1 and zero cases of virologic failure versus continuation of a 3-drug TAF-based regimen

08 Oct 2020
ViiV Healthcare announces dolutegravir plus lamivudine three-year data confirming long-term viral suppression non-inferior to a 3-drug regimen for treatment-naïve adults with HIV-1

05 Oct 2020
ViiV Healthcare to present long-term safety and efficacy data for 2-drug regimen Dovato (dolutegravir/lamivudine) alongside other key research advances at the HIV Glasgow 2020 congress

30 Sep 2020
ViiV Healthcare announces start of implementation science study to identify and evaluate approaches to integrating its investigational, every-two-month, injectable HIV treatment in European healthcare practices

28 Sep 2020
ViiV Healthcare announces data demonstrating the feasibility of Dovato (dolutegravir/lamivudine) as a treatment option for rapid initiation after diagnosis in adults with HIV-1

20 Aug 2020
ViiV Healthcare announces new strategic alliance to enable greater access to antiretroviral medicines in Brazil

15 Jul 2020
ViiV Healthcare announces superior efficacy of investigational, long-acting injectable formulation of cabotegravir dosed every two months over daily oral PrEP

07 Jul 2020
ViiV Healthcare shares new data from Positive Perspectives, Wave 2 study, confirming a more holistic approach to HIV care can improve quality of life

04 Jul 2020

High levels of engagement between healthcare providers and people living with HIV are associated with better health outcomes
ViiV Healthcare presents positive data from first-ever implementation research study on how best to integrate a investigational once-monthly injectable HIV treatment in US healthcare practices

04 Jul 2020
ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual)

02 Jul 2020
ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available

02 Jul 2020
ViiV Healthcare announces grantees selected as part of £3 million Fund dedicated to HIV research and community-based programmes during COVID-19 pandemic

30 Jun 2020
Welsh Rugby star Gareth Thomas and ViiV Healthcare launch Tackle HIV campaign to address public misunderstanding and stigma associated with HIV

24 Jun 2020
ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV

12 Jun 2020
Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP

18 May 2020
ViiV Healthcare announces £3 million global fund to research the impact of COVID-19 on the HIV community and fill gaps in prevention, treatment and care during the pandemic

27 Apr 2020
"ViiV Healthcare announces first global regulatory approval of CABENUVA; the first complete, long-acting, regimen for the treatment of HIV"

20 Mar 2020
ViiV Healthcare presents positive, 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing

09 Mar 2020
ViiV Healthcare presents positive long-term data from phase III study demonstrating efficacy and safety of cabotegravir and rilpivirine, its investigational, long-acting HIV-treatment regimen in adults living with HIV-1

09 Mar 2020
ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership

09 Mar 2020
ViiV Healthcare initiates study with the University of South Carolina to evaluate the benefits of ride-sharing services on improving access to care for people living with HIV

02 Mar 2020
Dovato (dolutegravir/lamivudine), the once-daily, single-pill, 2-drug regimen for the treatment of HIV-1 infection, granted marketing approval by Japan Ministry of Health, Labour and Welfare

15 Jan 2020
ViiV Healthcare submits regulatory application to the European Medicines Agency for investigational fostemsavir, a first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

10 Jan 2020
ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV

21 Dec 2019
ViiV Healthcare files submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children living with HIV

13 Dec 2019
ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

05 Dec 2019
ViiV Healthcare reaffirms future commitment to industry-leading Positive Action programmes over the next 10 years investing in global efforts to end AIDS epidemic

05 Dec 2019
ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb” with potential for long-acting HIV treatment and prevention

21 Nov 2019
ViiV Healthcare to present 17 abstracts from its portfolio, addressing the diverse needs of people living with HIV

06 Nov 2019
ViiV Healthcare’s commitment to support AIDS2020 and HIV2020

17 Oct 2019
IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV

02 Oct 2019
Stigma and mental health challenges remain barriers to good quality of life for people living with HIV in urban settings

11 Sep 2019
ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months

22 Aug 2019
Five years on, 3.9 million people in the developing world have access to HIV treatment dolutegravir, thanks to access-oriented voluntary licensing agreements

30 Jul 2019
ViiV Healthcare submits regulatory application to European Medicines Agency for investigational cabotegravir to be used in combination with rilpivirine as the first monthly, injectable treatment for HIV

29 Jul 2019
ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance

24 Jul 2019
ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection

24 Jul 2019
ViiV Healthcare presents positive 96-week data from phase III study of investigational fostemsavir in heavily treatment-experienced patients with HIV at IAS 2019

22 Jul 2019
ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen

10 Jul 2019
ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice

08 Jul 2019
ViiV Healthcare receives EU Marketing Authorisation for Dovato

03 Jul 2019
ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine

30 Apr 2019
ViiV Healthcare announces CHMP Positive Opinion for Dovato® (dolutegravir/lamivudine) as a once-daily, single-pill, two-drug regimen for the treatment of HIV infection

27 Apr 2019
US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults

09 Apr 2019
ViiV Healthcare announces Juluca maintains HIV viral suppression at 148-weeks

04 Apr 2019
Our commitments to paediatric HIV: Research partners share new dolutegravir data on treatment of HIV-infected children

14 Mar 2019
March

14 Mar 2019
ViiV Healthcare presents positive 48 week data from two pivotal phase III studies showing long acting injectable two drug regimen of cabotegravir and rilpivirine has similar efficacy to daily three drug oral treatment in adults living with HIV1 infection

07 Mar 2019
ViiV Healthcare announces collaboration with Radboud university to identify new drug targets for HIV

26 Feb 2019
ViiV Healthcare update on commitments regarding the clinical development and registration of age-appropriate formulations of dolutegravir for the treatment of HIV in infant and children

13 Dec 2018
Fast-Track Cities Survey Data Provide Insights into Quality of Life of People Living with HIV

30 Nov 2018
Juluca the first single pill 2 drug regimen for the maintenance treatment of HIV granted marketing approval by Japan Ministry of Health Labour and Welfare

26 Nov 2018
ViiV Healthcare receives CHMP Positive Opinion for Tivicay EU label update with GEMINI study data for the 2-drug regimen of Tivicay + lamivudine (1)

16 Nov 2018

CHMP Positive Opinion received for Tivicay EU label update with GEMINI study data for the 2-drug regimen of Tivicay + lamivudine
ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV

31 Oct 2018
ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen

30 Oct 2018

FLAIR study meets primary endpoint, showing similar efficacy of a once-a-month, investigational, injectable two-drug regimen of cabotegravir and rilpivirine compared to a daily, oral three-drug, integrase-based regimen in virally-suppressed adults.
ViiV Healthcare presents three year data for investigational long acting injectable two drug HIV regimen (1)

29 Oct 2018
ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV

18 Oct 2018

ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
ViiV Healthcare update on how we work with healthcare professionals

02 Oct 2018

ViiV Healthcare update on how we work with healthcare professionals
ViiV healthcare submits regulatory application to EMA for single tablet two drug regimen of dolutegravir and lamivudine for treatment of hiv

14 Sep 2018

ViiV Healthcare submits regulatory application to European Medicines Agency for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
ViiV Healthcare reports positive 48-week results for first pivotal, phase III study for novel, long-acting, injectable HIV-treatment regimen

15 Aug 2018
ViiV Healthcare reports positive 48-week results for first pivotal, phase III study for novel, long-acting, injectable HIV-treatment regimen

15 Aug 2018
ViiV Healthcare’s commitments to accelerate the availability of dolutegravir for the treatment of HIV in children

25 Jul 2018
ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018

24 Jul 2018

100-week results from the SWORD phase III programme evaluating the safety and efficacy of switching virologically suppressed patients from a three or four-drug antiretroviral regimen to a 2-drug regimen of dolutegravir. and rilpivirine.
ViiV Healthcare presents phase III data showing two drug regimen has similar efficacy to a three-drug regimen in treatment naïve HIV patients, with no resistance

24 Jul 2018

GEMINI 1 & 2 studies meet primary endpoint, showing two-drug regimen to be effective across high and low viral loads
ViiV Healthcare shares data from landmark 2-drug regimen trials at AIDS 2018

18 Jul 2018
Innovative public-private partnership initiative to accelerate development of optimal paediatric formulations of dolutegravir to improve the lives of CLHIV

18 Jul 2018
ViiV Healthcare reports positive results for landmark phase III studies for dolutegravir and lamivudine

14 Jun 2018
ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single-pill for the treatment of HIV

21 May 2018

Juluca maintains viral suppression with two drugs in the smallest single pill regimen
ViiV Healthcare gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe

23 Mar 2018

Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion for Juluca
ViiV Healthcare announces positive new dolutegravir data for the treatment of people living with HIV co-infected with tuberculosis

05 Mar 2018

INSPIRING study results contribute to the extensive body of evidence for dolutegravir, the leading integrase strand transfer inhibitor, in diverse and hard to treat patient populations
ViiV Healthcare launches eighth phase III study in two-drug regimen programme for HIV-1 treatment

08 Feb 2018

TANGO study will investigate dolutegravir (TIVICAY) and lamivudine (EPIVIR) in patients with HIV who have achieved viral suppression on a tenofovir alafenamide fumarate-based regimen
ViiV Healthcare files patent infringement litigation against Gilead Sciences Inc. over bictegravir

08 Feb 2018
ViiV Healthcare announces start of phase III study of long-acting cabotegravir for HIV prevention in women

30 Nov 2017

The HPTN 084 study will evaluate injections given every two months
ViiV Healthcare starts third phase III HIV treatment study investigating long-acting two-drug regimen of cabotegravir plus rilpivirine

28 Nov 2017
ViiV Healthcare announces US FDA approval for Juluca®

21 Nov 2017

Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection
ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV

27 Oct 2017

ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV
New results from the Positive Perspectives global survey provide insights into the attitudes and perceptions of people living with HIV

25 Oct 2017
Tivicay® and Celsentri® now included in the Essential Drug List in Russia

24 Oct 2017

Both medicines expected to be available in HIV specialist treatment centres from 2018 onwards
ViiV Healthcare and NEAT-ID announce results from the NEAT 022 study at the International AIDS Society meeting in Paris

25 Jul 2017

Collaborative study of dolutegravir treatment in patients with HIV and high CV risk
ViiV Healthcare announces superior efficacy of dolutegravir versus lopinavir/ritonavir in second-line HIV treatment in resource-limited settings

25 Jul 2017

Results of DAWNING to find efficacy of DTG versus LPV/RTV plus 2 NRTIs in second-line treatment announced
Phase II study results showed comparable viral suppression rates at 96 weeks for a two-drug regimen

24 Jul 2017

Comparable viral suppression rates at 96 weeks for a two drug regimen of long acting dolutegravir and rilpivirine and a three drug regimen in patients with HIV
ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017

20 Jul 2017

Press release for HIV research presented at IAS 2017
ViiV Healthcare’s Positive Action Europe Programme awards grants to 14 community-based organisations

14 Jun 2017

Positive Action Europe fourth grant cycle comes to a close as 14 patient advocacy organisations across Europe have been awarded grants to deliver education, support services and care for people living with HIV
ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines

01 Jun 2017

First regulatory submissions for two drug HIV treatment regimen
Honoring the memory of Dr Mark Wainberg

13 Apr 2017
ViiV Healthcare ranks #1 in PatientView corporate reputation survey

21 Mar 2017
ViiV Healthcare welcomes European Commission approval of dolutegravir paediatric Type II variation and extension applications

27 Feb 2017
ViiV Healthcare announces detailed positive phase III results for investigational two-drug regimen of dolutegravir and rilpivirine for HIV treatment

13 Feb 2017
ViiV Healthcare awards grants to MSM and Transgender HIV programmes led by the community for the community

12 Jan 2017
ViiV Healthcare re-affirms its continued commitment to ending mother- to- child transmission of HIV with 35 new community grants

11 Jan 2017
ViiV Healthcare announces start of phase III study evaluating long-acting cabotegravir for HIV prevention

20 Dec 2016
ViiV Healthcare announces positive results from first phase III studies of two-drug HIV treatment regimen

19 Dec 2016
ViiV Healthcare Announces CHMP positive opinion to lower the age and weight limit for dolutegravir in children and adolescents living with HIV in Europe

16 Dec 2016
"Dominique Limet to step down as CEO of ViiV Healthcare; Deborah Waterhouse to succeed him"

05 Dec 2016
New agreement with Ministry of Health will enable access to dolutegravir for the treatment of HIV under the national health programme in Brazil

01 Dec 2016
ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen

18 Nov 2016
ViiV Healthcare Announces FDA Approval of SELZENTRY® (maraviroc) for Use in Children and Adolescents Living With HIV

11 Nov 2016
ViiV Healthcare’s Positive Action Europe Invites Applications for 2017 Grants Scheme

24 Oct 2016
ViiV Healthcare welcomes the FDA’s Tentative Approval of the first generic dolutegravir from Aurobindo Pharma

22 Sep 2016
Every Woman, Every Child and ViiV Healthcare Announce the Winner of ‘Empowering Girls in Emergency Settings’ Challenge Prize

21 Sep 2016
New HIV Awareness in Primary Care campaign launched to increase primary care HIV testing

20 Sep 2016
ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment

16 Aug 2016
ARIA study shows superior efficacy of Triumeq® for treatment-naïve women living with HIV

18 Jul 2016
ViiV Healthcare joins PENTA Foundation in search for strategies to achieve remission in children living with HIV

29 Jun 2016

ViiV Healthcare joins PENTA Foundation in search for strategies to achieve remission in children living with HIV
ViiV Healthcare announces FDA approval to lower the weight limit for dolutegravir in children and adolescents living with HIV

10 Jun 2016

ViiV Healthcare announces FDA approval to lower the weight limit for dolutegravir in children and adolescents living with HIV
ViiV Healthcare announces public tender agreement with Botswana Ministry of Health for dolutegravir

03 Jun 2016

ViiV Healthcare announces public tender agreement with Botswana Ministry of Health for dolutegravir
ViiV Healthcare and the International Association of Providers of AIDS Care to Collaborate on Fast-Track Cities

31 May 2016

ViiV Healthcare and the International Association of Providers of AIDS Care to Collaborate on Fast-Track Cities
ViiV Healthcare extends Medicines Patent Pool licence agreement for dolutegravir to cover all lower middle-income countries

25 Apr 2016

ViiV Healthcare extends Medicines Patent Pool licence agreement for dolutegravir to cover all lower middle-income countries
Global partnership launches new programme with goal to save the lives of thousands of children affected by HIV in Lesotho

08 Apr 2016

Global partnership launches new programme with goal to save the lives of thousands of children affected by HIV in Lesotho
ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir

24 Feb 2016

ViiV Healthcare announces public tender agreement with Botswana Ministry of Health for dolutegravir
ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment

23 Feb 2016

ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment
ViiV Healthcare to progress collaboration with Janssen to develop the first long-acting, two drug injectable regimen for treatment of HIV

07 Jan 2016

ViiV Healthcare
ViiV Healthcare to acquire Bristol-Myers Squibb HIV R&D assets

18 Dec 2015

Two transactions strengthen ViiV Healthcare’s position at the forefront of HIV innovation
ViiV Healthcare highlights its continued commitment to end mother to child transmission of HIV

30 Nov 2015

ViiV Healthcare highlights its continued commitment to end mother to child transmission of HIV
ViiV Healthcare at ICASA: Improving Access to HIV Treatment and Care for People Everywhere

29 Nov 2015

ViiV Healthcare at ICASA: Improving Access to HIV Treatment and Care for People Everywhere
ViiV Healthcare gets ready for Africa’s largest HIV-AIDS Conference

27 Nov 2015

ViiV Healthcare gets ready for Africa’s largest HIV-AIDS Conference
ViiV Healthcare Awards Additional Round of Grants to Support Innovative HIV Programs Aimed at Reducing Disparities in the Southern US

20 Nov 2015

ViiV Healthcare Awards Additional Round of Grants to Support Innovative HIV Programs Aimed at Reducing Disparities in the Southern US
ViiV Healthcare announces positive headline results from a study of two drug injectable regimen for HIV maintenance therapy

03 Nov 2015

ViiV Healthcare announces positive headline results from a study of two drug injectable regimen for HIV maintenance therapy
ViiV Healthcare awards 23 small grants to help alleviate the stigma of HIV and AIDS in the MSM and transgender community globally

26 Oct 2015

ViiV Healthcare awards 23 small grants to help alleviate the stigma of HIV and AIDS in the MSM and transgender community globally
ViiV Healthcare employee named top marketer in healthcare industry, by Medical Marketing & Media

13 Oct 2015

ViiV Healthcare employee named top marketer in healthcare industry, by Medical Marketing & Media
New Phase IIIb/IV data show switching to once-daily Triumeq® maintains HIV viral suppression

23 Sep 2015

New Phase IIIb/IV data show switching to once-daily Triumeq® maintains HIV viral suppression
ViiV Healthcare and Desano Pharmaceuticals’ manufacturing agreement will allow competitive supply of dolutegravir in China and several developing countries

02 Jul 2015

ViiV Healthcare and Desano Pharmaceuticals’ manufacturing agreement will allow competitive supply of dolutegravir in China and several developing countries
ViiV Healthcare Announces New Positive Action Project in US for MSM Youth, Calls for Proposals

22 Jun 2015

ViiV Healthcare Announces New Positive Action Project in US for MSM Youth, Calls for Proposals
ViiV Healthcare and CHAI collaboration delivers second milestone with first filing with the FDA of generic dolutegravir by Aurobindo Pharma for the treatment of HIV

26 May 2015

ViiV Healthcare and CHAI collaboration delivers second milestone with first filing with the FDA of generic dolutegravir by Aurobindo Pharma for the treatment of HIV
European Patient Advocacy Groups Awarded Grants from Positive Action Europe

13 May 2015

European Patient Advocacy Groups Awarded Grants from Positive Action Europe
ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy

06 May 2015

ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy
ViiV Healthcare Launches New Global Positive Action Programme Focused on MSM and Transgender Populations

31 Mar 2015

ViiV Healthcare Launches New Global Positive Action Programme Focused on MSM and Transgender Populations
ViiV Healthcare announces the approval in Japan of Triumeq® (dolutegravir, abacavir and lamivudine), a new single-pill regimen for the treatment of HIV infection

16 Mar 2015

ViiV Healthcare announces the approval in Japan of Triumeq® (dolutegravir, abacavir and lamivudine), a new single-pill regimen for the treatment of HIV infection
ViiV Healthcare Announces $10 Million Initiative to Accelerate Response to HIV/AIDS Among Black Gay and Bisexual Men

04 Feb 2015

ViiV Healthcare Announces $10 Million Initiative to Accelerate Response to HIV/AIDS Among Black Gay and Bisexual Men
ViiV Healthcare announces regulatory submission in Japan for single-pill regimen combining dolutegravir, abacavir and lamivudine for the treatment of HIV

15 Dec 2014

ViiV Healthcare announces regulatory submission in Japan for single-pill regimen combining dolutegravir, abacavir and lamivudine for the treatment of HIV
Mylan's tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and CHAI

04 Dec 2014

Mylan's tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and CHAI
ViiV Healthcare announces new grants in support of ending mother to child transmission of HIV

27 Nov 2014

ViiV Healthcare announces new grants in support of ending mother to child transmission of HIV
HIV Testing Week

21 Nov 2014

HIV Testing Week
GSK ranked top of the 2014 Access to Medicines (ATM) Index for the fourth consecutive time

18 Nov 2014

GSK ranked top of the 2014 Access to Medicines (ATM) Index for the fourth consecutive time
ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern US

20 Oct 2014

ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern US
ViiV Healthcare receives FDA approval for Triumeq

22 Aug 2014

ViiV Healthcare receives FDA approval for Triumeq
ViiV Healthcare presents phase III data comparing once-daily maraviroc

22 Jul 2014

ViiV Healthcare presents phase III data comparing once-daily maraviroc
ViiV Healthcare announces new collaboration with Janssen

12 Jun 2014

ViiV Healthcare announces new collaboration with Janssen
ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool

01 Apr 2014

ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool
ViiV Healthcare Announces Next Round of the Positive Action Southern Initiative to Support Linkages to HIV/AIDS Care and Treatment Adherence

19 Mar 2014

ViiV Healthcare Announces Next Round of the Positive Action Southern Initiative to Support Linkages to HIV/AIDS Care and Treatment Adherence
ViiV Healthcare’s new HIV medicine Tivicay™ (dolutegravir) is approved in Europe

21 Jan 2014

ViiV Healthcare today announced that the European Commission has approved TivicayTM (dolutegravir), an integrase inhibitor, for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age.
ViiV Healthcare to Make Available Anonymised Patient-Level Data from its Clinical Trials

02 Jan 2014

ViiV Healthcare to Make Available Anonymised Patient-Level Data from its Clinical Trials
Update on patent ruling on ViiV Healthcare’s Epzicom® and Trizivir®

17 Dec 2013

GSK and ViiV Healthcare confirmed today that the US District Court for the District of Delaware upheld the validity of a patent covering the double combination of lamivudine and abacavir (Epzicom®) and the triple combination of lamivudine, abacavir and zidovudine (Trizivir®).
ViiV Healthcare commits £3.4M in Positive Action for Children Fund grants for programmes focused on prevention of mother-to-child transmission of HIV

10 Dec 2013

Latest round of Positive Action for Children Fund grants brings total funding for programmes that empower women and children to £20 million to date.
ViiV Healthcare announces European regulatory submission for single-tablet regimen

25 Oct 2013

ViiV Healthcare announces European regulatory submission for single-tablet regimen
ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV

22 Oct 2013

ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV
ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naïve Adults with HIV-1

12 Sep 2013

ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naïve Adults with HIV-1
ViiV Healthcare Expands HIV/AIDS Community Support in Hard-Hit Southern US

04 Sep 2013

ViiV Healthcare Expands HIV/AIDS Community Support in Hard-Hit Southern US
ViiV Healthcare announces US approval of Tivicay® (dolutegravir) for the treatment of HIV-1

13 Aug 2013

ViiV Healthcare announces US approval of Tivicay® (dolutegravir) for the treatment of HIV-1
ViiV Healthcare presents data from Phase III study of dolutegravir vs raltegravir in treatment-experienced adults with HIV-1

06 Mar 2013

ViiV Healthcare presents 24-week interim results from Phase III SAILING study of dolutegravir
ViiV Healthcare announces a voluntary licence agreement with the Medicines Patent Pool to increase access to HIV medicines for children

27 Feb 2013

Medicines Patent Pool, voluntary licence, access, dolutegravir, abacavir
ViiV Healthcare announces FDA priority review designation for dolutegravir as a potential treatment for HIV infection

15 Feb 2013

dolutegravir, priority review, FDA
ViiV Healthcare expands Positive Action Southern Initiative to fight HIV/AIDS and support community action

04 Feb 2013

Positive Action Southern Initiative community action
ViiV Healthcare announces regulatory submissions for dolutegravir in the EU, US and Canada

17 Dec 2012

ViiV Healthcare announces regulatory submissions for dolutegravir in the EU, US and Canada
ViiV Healthcare presents phase III data from VIKING-3 study of dolutegravir in HIV-1 infected integrase inhibitor-resistant adults

13 Nov 2012

ViiV Healthcare presents phase III data from VIKING-3 study of dolutegravir in HIV-1 infected integrase inhibitor-resistant adults
ViiV Healthcare commits nearly £4M in Positive Action for Children Fund grants for programmes focused on alleviating burden of HIV on women and children

08 Nov 2012

ViiV Healthcare commits nearly £4M in Positive Action for Children Fund grants for programmes focused on alleviating burden of HIV on women and children
Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio

28 Oct 2012

Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio
Shionogi-ViiV Healthcare announces completion of initial clinical registration package for dolutegravir in HIV

04 Oct 2012

complete clinical registration package for dolutegravir
ViiV Healthcare Expands Support for HIV Prevention and Education in Hard-Hit US Region

31 Jul 2012

ViiV Healthcare Expands Support for HIV Prevention and Education in Hard-Hit US Region
Once-Daily Dolutegravir is Non-Inferior to Twice-Daily Raltegravir in Treatment-Naïve Adults with HIV-1

26 Jul 2012

Once-Daily Dolutegravir is Non-Inferior to Twice-Daily Raltegravir in Treatment-Naïve Adults with HIV-1
ViiV Healthcare Expands Commitment to Addressing Gaps in Paediatric HIV Research, Care and Treatment

18 Jul 2012

ViiV Healthcare Expands Commitment to Addressing Gaps in Paediatric HIV Research, Care and Treatment
Shionogi – ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV

11 Jul 2012

Shionogi – ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV
Shionogi – ViiV Healthcare announces initial data from Pivotal Phase III study of dolutegravir in HIV

02 Apr 2012

Shionogi – ViiV Healthcare announces initial data from Pivotal Phase III study of dolutegravir in HIV
Media Alert: ViiV Healthcare’s Positive Action for Children Fund announces 16 new grantees for the year 2011/2012

13 Oct 2011

Media Alert: ViiV Healthcare’s Positive Action for Children Fund announces 16 new grantees for the year 2011/2012
ViiV Healthcare starts phase III programme of Celsentri/Selzentry versus Truvada in combination with a protease inhibitor in people living with HIV

11 Oct 2011

ViiV Healthcare starts phase III programme of Celsentri/Selzentry versus Truvada in combination with a protease inhibitor in people living with HIV
ViiV Healthcare Reaffirms Commitment to US Regions Hardest Hit by HIV/AIDS

26 Sep 2011

ViiV Healthcare Reaffirms Commitment to US Regions Hardest Hit by HIV/AIDS
Regulatory Update – Celsentri/Selzentry® (maraviroc)

20 Sep 2011

Regulatory Update – Celsentri/Selzentry® (maraviroc)
ViiV Healthcare Awards Small Grants from Positive Action for Children Fund to 82 Charitable Organisations Globally

20 Jun 2011

ViiV Healthcare Awards Small Grants from Positive Action for Children Fund to 82 Charitable Organisations Globally
ViiV Healthcare Expands Positive Action US Southern Initiative to Fight HIV/AIDS in Hard-hit Region

04 Apr 2011

ViiV Healthcare Expands Positive Action US Southern Initiative to Fight HIV/AIDS in Hard-hit Region
Regulatory Update – Celsentri/Selzentry® (maraviroc)

04 Mar 2011

Regulatory Update – Celsentri/Selzentry® (maraviroc)
David Redfern appointed as Chairman of the Board for ViiV Healthcare

25 Feb 2011

David Redfern appointed as Chairman of the Board for ViiV Healthcare
Positive Action and Vida Digna - further information

14 Feb 2011

Positive Action and Vida Digna - further information
ViiV Healthcare’s Positive Action and the International HIV/AIDS Alliance Tackle HIV Stigma in Six Central American Countries

14 Feb 2011

ViiV Healthcare’s Positive Action and the International HIV/AIDS Alliance Tackle HIV Stigma in Six Central American Countries
Global Agenda for Elimination of Mother to Child Transmission of HIV: Positive Action for Children Fund Calls for Proposals to Fill the Gaps

15 Dec 2010

Global Agenda for Elimination of Mother to Child Transmission of HIV: Positive Action for Children Fund Calls for Proposals to Fill the Gaps
Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor

21 Oct 2010

Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor
ViiV Healthcare acts to improve access to HIV Medicines in United States for those most in need

12 Oct 2010

ViiV Healthcare acts to improve access to HIV Medicines in United States for those most in need
ViiV Healthcare Awards Southern Initiative Grants to Reduce HIV Disparities Among African Americans and Latinos

09 Sep 2010

Southern Initiative, Positive Action, Grants
Shionogi - ViiV Healthcare Announces Commitment to Phase III Development Programme for Investigational Once-Daily HIV Integrase Inhibitor

21 Jul 2010

Shionogi - ViiV Healthcare Announces Commitment to Phase III Development Programme for Investigational Once-Daily HIV Integrase Inhibitor
Positive Phase IIb Data on Investigational Once-Daily Integrase Inhibitor, 572, presented at International AIDS Conference

21 Jul 2010

Positive Phase IIb Data on Investigational Once-Daily Integrase Inhibitor, 572, presented at International AIDS Conference
ViiV Healthcare Announces Positive Action US Southern Initiative, an Innovative Community Support Program to Fight HIV/AIDS

06 Jul 2010

ViiV Healthcare Announces Positive Action US Southern Initiative, an Innovative Community Support Program to Fight HIV/AIDS
ViiV Healthcare Awards Grants from the Positive Action for Children Fund of £3.6m

30 Jun 2010

ViiV Healthcare Awards Grants from the Positive Action for Children Fund of ?3.6m
ViiV Healthcare and amfAR Partner to Optimize HIV Treatment for Infants and Children in Asia

17 Jun 2010

ViiV Healthcare and amfAR Partner to Optimize HIV Treatment for Infants and Children in Asia
ViiV Healthcare and Elizabeth Glaser Paediatric AIDS Foundation Partner to Expedite Access to ARV Treatment for Infants and Children

07 Jun 2010

ViiV Healthcare and Elizabeth Glaser Paediatric AIDS Foundation Partner to Expedite Access to ARV Treatment for Infants and Children
ViiV Healthcare Calls for Initial Grant Proposals to the Positive Action for Children Fund

22 Mar 2010

ViiV Healthcare Calls for Initial Grant Proposals to the Positive Action for Children Fund
FDA Approves Expanded Use of Selzentry® for Appropriate Patients Starting HIV Antiretroviral Therapy for the First Time

20 Nov 2009

FDA Approves Expanded Use of Selzentry® for Appropriate Patients Starting HIV Antiretroviral Therapy for the First Time
ViiV Healthcare Launches

03 Nov 2009

ViiV Healthcare Launches
GlaxoSmithKline and Pfizer announce innovative agreement to create a new world-leading, specialist HIV company

16 Apr 2009

GlaxoSmithKline and Pfizer announce innovative agreement to create a new world-leading, specialist HIV company
2023
February
September
December
February
October
March
May
July
June
2018
December
November
October
August
September
July
June
May
April
February
2020
January
March
January
July
June
August
April
March
November
2014
October
December
June
May
March
February
January
October
December
May
july
February
2022
March
January
April
2009
November
April
June
September
March
October
December
2010
July
June
March
September
April
October
February
2011
December
October
July
2012
November
April
March
February
August
December
September
October
2013
February
March
June
May
July
September
December
November
2015
October
January
June
February
April
May
August
July
September
2016
October
November
December
January
April
February
March
June
2017
October
November
July
December
November
October
August
September
July
February
2019
April
December
September
October
July
2021

These press releases and news updates are intended for media and investors only

Significant milestone for HIV prevention in Sub-Saharan Africa as South Africa grants regulatory approval for Apretude

01 Dec 2022
ViiV Healthcare Launches GIPA Accelerator Fund to support community-led initiatives in efforts to end AIDS by 2030

08 Nov 2022

ViiV Healthcare is launching the GIPA Accelerator Fund to support community-led and community-driven national and regional efforts to end AIDS by 2030. We strongly believe that engaging local communities is critical to addressing the drivers of health inequalities, and therefore strive to promote community responses that change beliefs, attitudes, and behaviours to improve health and rights at the community level.
Progress in our commitment to enabling access to cabotegravir long-acting for HIV prevention, as first sub-saharan African country approves Apretude

19 Oct 2022
ViiV Healthcare is working with Medicines Patent Pool to progress voluntary licensing for cabotegravir long-acting for PrEP

04 Apr 2022
Our response to the situation in Ukraine

22 Mar 2022
ViiV Healthcare open to voluntary licensing as part of approach to enable greater access to cabotegravir LA for PrEP in low- and middle-income countries

05 Mar 2022
ViiV Healthcare presents real-world evidence at EACS 2021 reinforcing the use of its 2-drug regimens Dovato (dolutegravir/lamivudine) and Juluca▼ (dolutegravir/rilpivirine) for the treatment of people living with HIV

28 Oct 2021
ViiV Healthcare Launches HIV Prevention Fund to support community-led initiatives in efforts to end AIDS by 2030

16 Jul 2021
ViiV Healthcare retains #1 position for eighth year in a row in PatientView’s ‘Corporate Reputation of Pharma – from the Patient Perspective 2020 - 2021’ survey results

27 Apr 2021
Evolving our approach to access in Azerbaijan, Belarus, Kazakhstan and Malaysia

26 Apr 2021
Building on our inclusion and diversity commitments by announcing gender and diversity aspirational targets to increase representation at senior levels

17 Feb 2021
ViiV Healthcare statement on Mylan’s FDA tentative approval for a scored 10mg dolutegravir (DTG) dispersible tablet formulation

24 Nov 2020
Algeria gains inclusion to ViiV Healthcare and MPP Adult licence enabling greater access to dolutegravir-based HIV treatments

12 Oct 2020
Our commitment to solutions continues: HIV and COVID-19 Emergency Response Fund grantees selected

03 Jul 2020
ViiV Healthcare and Medicine Patent Pool statement on voluntary licences in enabling access to fostemsavir

02 Jul 2020
"Our commitment to solutions; the ViiV Healthcare Global HIV and COVID-19 Emergency Response Fund"

27 Apr 2020
Update on ViiV’s response to COVID-19

21 Apr 2020
ViiV Healthcare ranks #1 company in the PatientView ‘Corporate Reputation of Pharma – from the Patient Perspective 2019 – 2020’ survey

21 Apr 2020
ViiV Healthcare’s commitment to support AIDS2020 and key conferences during COVID19 outbreak

31 Mar 2020
COVID-19 Guidance to Investigators

27 Mar 2020
ViiV’s position on COVID-19 outbreak

17 Mar 2020

Media contacts

Media contact details for our global headquarters and USA. For press contacts in our local operating companies please visit our country websites.

In you have a media query please use our Contact our team form here.

Global Press Office

Rachel Jaikaran
Head of Global Communications ViiV Healthcare
Tel: +44 7909 00240

US Press Office

Audrey Abernathy
Head of ViiV US External Affairs & Communications
Tel: +1 919 605 4521

NP-GBL-HVX-COCO-220024 November 2021.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.